NanoNewron
Private Company
Total funding raised: $24.5M
Overview
NanoNewron is a private, preclinical-stage biotech based in San Diego, spun out from Rutgers University, with a mission to treat neurodegenerative diseases by enabling biologic delivery across the Blood-Brain Barrier. The company's patented NewroBus™ platform utilizes humanized camelid nanobodies that exploit Transferrin Receptor 1 (TfR1)-mediated transcytosis to shuttle therapeutic payloads into the brain. Its lead program, NN-843, targets Tumor Necrosis Factor-alpha (TNF-α) for Alzheimer's Disease, a pathway with strong scientific rationale but previously inaccessible to approved biologics. The company is led by an experienced team, including CEO Marco Taglietti, who has a track record of bringing drugs to market, and founder/CSO Dr. Luciano D'Adamio, a distinguished neuroscientist.
Technology Platform
NewroBus™: A patented platform of humanized, single-chain camelid nanobodies (VHH) that exploit Transferrin Receptor 1 (TfR1)-mediated transcytosis to shuttle therapeutic biologics across the Blood-Brain Barrier (BBB).
Funding History
2Opportunities
Risk Factors
Competitive Landscape
NanoNewron competes in the crowded Alzheimer's therapeutic space, which includes large pharma (Biogen/Eisai, Lilly) and other biotechs targeting amyloid, tau, and inflammation. Its specific differentiation is its BBB shuttle technology, competing directly with other companies developing receptor-mediated transcytosis platforms (e.g., targeting TfR1, insulin receptor, or LDL receptor) to deliver biologics to the brain.